evipedia.ai
← Back

MSM for Health & Longevity

Evidence Review created on 10/15/2026 using AI4L / Opus 5.5

Also known as: Methylsulfonylmethane, Methylsulphonylmethane, Dimethyl Sulfone, Methyl Sulfone, DMSO2, Crystalline DMSO, Sulfonylbismethane, OptiMSM

Motivation

Methylsulfonylmethane (MSM, also called dimethyl sulfone) is a small sulfur-containing compound found in trace amounts in fruits, vegetables, grains, milk and coffee, and also formed inside the body. Sold as an inexpensive, odorless white powder or capsule, it is one of the most widely used joint supplements and is often combined with glucosamine and chondroitin. Interest rests on the idea that it supplies sulfur for connective tissue and calms inflammation.

The compound came to attention in the 1960s as the main breakdown product of a solvent then being explored for pain and swelling. It has since been studied in people with knee arthritis, in runners and other active adults, and in people with seasonal allergies. A large share of this research was carried out or supported by companies that make or sell the product.

This review examines what the human evidence shows for joint comfort, exercise recovery and allergies, what is known about safety, interactions and dosing, and where the gaps lie, for health-focused adults weighing whether MSM belongs in a longevity routine.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and key papers that give a high-level view of MSM and its evidence.

  • What is MSM? - Laurie Mathena

    Life Extension Magazine overview of the knee-osteoarthritis trials and the glucosamine-chondroitin combination data. Life Extension sells MSM products, so the framing is favorable and selective.

  • Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement - Butawan et al., 2017

    The most widely cited narrative review of MSM’s uses, dosing and safety. One co-author is affiliated with Bergstrom Nutrition, the maker of the OptiMSM ingredient.

Only two items qualified. Rhonda Patrick’s MSM content is limited to members-only FoundMyFitness episodes (a glucosamine-chondroitin-MSM segment in Q&A #53 and a brief question in Q&A #75), which are not publicly accessible. Chris Kresser mentions MSM only in passing, as a sulfur source in two podcast episodes on sulforaphane and gut bacterial overgrowth, too brief to qualify. Web and on-site searches found no content discussing MSM from Peter Attia, Andrew Huberman or Lifespan.io; other candidates were narrow single studies, product pages, encyclopedias, consumer media or systematic reviews covered in other sections.

Grokipedia

  • Methylsulfonylmethane

    AI-written encyclopedia entry covering chemistry, food sources, proposed anti-inflammatory pathways, the osteoarthritis trials and regulatory status; useful orientation, though its evidence summaries are machine-generated.

Examine

  • MSM benefits, dosage, and side effects

    Examine’s evidence-graded MSM page, summarizing studied doses of 500 mg to 6 g/day over 10 days to 16 weeks and grading the osteoarthritis, exercise and other outcomes.

ConsumerLab

Systematic Reviews

This section lists systematic reviews and meta-analyses that evaluated MSM, mostly for osteoarthritis.

No systematic review dedicated to MSM’s harms was found; Liu et al., 2018 is the only listed review that pooled safety outcomes.

Mechanism of Action

MSM ((CH₃)₂SO₂) is the fully oxidized form of DMSO. Small amounts arise when gut bacteria break down the sulfur amino acid methionine (He & Slupsky, 2014).

  • Absorption and half-life: In rats, an oral dose peaks in blood at about 2 hours, has a half-life (time for blood levels to halve) of 12.2 hours and is about 86% recovered in urine (Magnuson et al., 2007).
  • Distribution: In people it reaches brain tissue within 10 minutes of intake (Kaiser et al., 2020).
  • Metabolism and selectivity: It has no defined receptor target. In mice it did not induce CYP enzymes (cytochrome P450, the liver’s main drug-processing enzymes) (Kutanzi et al., 2020); human metabolism is uncharacterized.
  • Sulfur donation: In mice, labeled sulfur from MSM was built into blood, liver and gut proteins, possibly via gut bacteria, in work co-authored by Bergstrom Nutrition staff (Wong et al., 2017).
  • Anti-inflammatory signaling: In human arthritic cartilage cells it blocked activation of NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) by IL-1β (interleukin-1 beta, an inflammatory messenger) and limited cartilage-degrading enzymes (Cheleschi et al., 2018).
  • Competing view: Methionine and cysteine are the main dietary sulfur sources, and no human sulfur deficiency corrected by MSM has been shown. In a partly Bergstrom-funded trial in overweight adults, inflammatory signaling proteins did not change versus placebo, while a lower C-reactive protein (a general inflammation marker) reflected a rise on placebo (Miller et al., 2021), so cell-culture mechanisms may overstate human effects.

Historical Context & Evolution

MSM entered medicine through DMSO, a wood-pulp by-product used as an industrial solvent. In the 1960s, surgeon Stanley Jacob at the University of Oregon Medical School investigated DMSO for pain and inflammation, and MSM was identified as its main oxidized product in the body.

Chemist Robert Herschler, Jacob’s collaborator, patented MSM as a dietary sulfur source (US Patent 4,616,039, 1986); the patent was later assigned to Bergstrom Nutrition. MSM was marketed as an odorless alternative to DMSO, and the 1999 book “The Miracle of MSM” by Jacob, Ronald Lawrence and Martin Zucker popularized it on the basis of clinical observation rather than controlled trials.

The first placebo-controlled trials followed. An Indian trial found that MSM, glucosamine and their combination each reduced knee osteoarthritis pain and swelling versus placebo (Usha & Naidu, 2004), and a US pilot using Bergstrom’s OptiMSM ingredient found less pain and better function at 6 g/day (Kim et al., 2006). Reviewers judged these results positive but not definitive (Brien et al., 2008), and a pooled analysis with DMSO trials found no significant effect (Brien et al., 2011).

In 2008 the FDA (U.S. Food and Drug Administration) closed Bergstrom’s GRAS (Generally Recognized as Safe) food-ingredient notice with “no questions” (FDA GRAS Notice No. 229). Later, a larger trial in healthy trainees found no benefit (Tennent et al., 2017) and a back-pain trial posted similar group scores (NCT02268305), while a newer review still ranks MSM among the better-performing osteoarthritis supplements (Chen et al., 2025), so its standing remains open.

Expected Benefits

High 🟩 🟩 🟩

Knee pain and function ⚠️ Conflicted

In osteoarthritis, 1.5–6 g/day beat placebo in independent trials led by Usha, Kim and Debbi (Usha & Naidu, 2004; Kim et al., 2006; Debbi et al., 2011); a 26-week trial (NCT01836757) reportedly agreed (an MSM seller’s magazine). A Chlorella Industry trial eased mild pain (Toguchi et al., 2023); OptiMSM did not prevent trainees’ knee pain (Tennent et al., 2017). Pooled with DMSO trials, relief was non-significant (Brien et al., 2011); a broader pool found significant but unclear relief (Liu et al., 2018). Net: a modest, uncertain short-term benefit is likely.

Magnitude: On 100 mm WOMAC scales, physical function improved 14.6 mm more than placebo (95% CI, confidence interval: the range likely to hold the true effect, 4.3 to 25.0) and total score 15.0 mm more (95% CI 5.1 to 24.9); the pain difference of 12.4 mm (95% CI 0.0 to 24.8) was not significant (Debbi et al., 2011).

Medium 🟩 🟩

Facial skin aging signs ⭕️ Not Central to Health & Longevity

In a 20-person pilot, 3 g/day for 16 weeks reduced facial wrinkles and skin roughness versus placebo, and a 63-person comparison of 1 g and 3 g without placebo found improved wrinkles, firmness, elasticity and hydration from baseline (Muizzuddin & Benjamin, 2022). One author is affiliated with Bergstrom Nutrition, the OptiMSM maker, and no independent replication exists. The outcome bears on appearance rather than health or lifespan.

Magnitude: Expert-graded facial wrinkles fell significantly over 16 weeks at 3 g/day while placebo changed only slightly; the paper presents these results in figures only, and the literature reports no numerical outcome figure (Muizzuddin & Benjamin, 2022).

Low 🟩

Low back pain ⚠️ Conflicted

MSM is promoted for back pain, but the only controlled trial, 6 g/day added to naproxen in 100 military beneficiaries for 12 weeks, posted similar pain scores with MSM and placebo (NCT02268305; safety analysis: Crawford et al., 2019). No positive back-pain trial exists. Net: no benefit has been shown.

Magnitude: Back pain at 12 weeks, when dosing ended, was 2.7 with MSM versus 3.2 with placebo on a 0–10 scale (baselines 3.4 and 3.7), not compared between groups in the posted results (NCT02268305).

In 22 half-marathon runners, 3 g/day of OptiMSM cut pain by over 10 mm, not significantly versus placebo (Withee et al., 2017). A placebo-free dose comparison in 8 men, funded by TandemRain Innovations, showed only a trend (Kalman et al., 2012). Net: no controlled trial shows a significant reduction.

Magnitude: Muscle pain 15 minutes after the race was 19.8 mm lower than placebo on a 100 mm scale (95% CI −43.7 to 4.1), not statistically significant (Withee et al., 2017).

Seasonal allergy symptoms

An open-label study (participants knew what they took) of 2.6 g/day for 30 days in 50 adults (Barrager et al., 2002) and a Bergstrom-sponsored randomized dose comparison (Hewlings & Kalman, 2018) reported fewer nasal symptoms. Neither had a placebo group.

Magnitude: Average nasal symptom scores fell 53.7% from baseline across the 1–6 g/day groups over 14 days (no control group) (Hewlings & Kalman, 2018).

High-density lipoprotein cholesterol in overweight adults ⚠️ Conflicted

In a partly Bergstrom-funded trial in 22 overweight adults, 3 g/day for 16 weeks raised HDL (high-density lipoprotein, the “good” cholesterol carrier) versus baseline but not versus placebo; glucose, insulin, LDL (low-density lipoprotein, “bad” cholesterol) and blood pressure were unchanged (Miller et al., 2021). Net: no effect versus placebo.

Magnitude: Over 16 weeks, HDL went from 44.9 to 51.8 mg/dL with MSM and from 42.7 to 48.0 mg/dL with placebo, with no significant difference between groups (Miller et al., 2021).

Hair and nail condition ⭕️ Not Central to Health & Longevity

A Bergstrom-authored comparison of 1 g and 3 g/day in 63 adults for 16 weeks, without placebo, reported better expert-graded hair and nail condition (Natural Medicine Journal 2019, now offline; a trade-press report). Kitten data agree (Guo et al., 2022). It bears on appearance.

Magnitude: Hair and nail condition improved from baseline at both doses over 16 weeks, sooner at 3 g/day (hair shine by week 4 versus week 8 at 1 g), with no control group; the available report gives no outcome figure (a trade-press report).

Speculative 🟨

Oxidative stress and inflammation markers ⚠️ Conflicted

A small Iranian trial reported lower oxidation markers after running (Nakhostin-Roohi et al., 2011); a US trial found none (Withee et al., 2017). These markers are unvalidated. Net: inconsistent.

Cancer prevention

MSM reduced breast cancer cell viability and growth signals in cells and mouse tumor grafts (Lim et al., 2012). No human data exist; the basis is laboratory only.

Bone density

Injected MSM increased jaw bone density in aging female mice (Aljohani et al., 2021). The route (injection) differs from oral use. No human bone data exist.

Lifespan and healthy aging

No study has shown longer life with MSM. The basis is extrapolation from anti-inflammatory data; the only lifespan observation, in mutant worms, found shorter life (Goldstein et al., 1992).

Benefit-Modifying Factors

  • Genetic polymorphisms: No study has examined gene variants that change MSM response. It is not known to be processed by variable drug-metabolizing enzymes, so no gene-based difference in response is expected.
  • Baseline symptom severity: Most positive trials enrolled people with knee osteoarthritis; one also found benefit for mild knee pain (Toguchi et al., 2023), while pain-free military trainees saw none (Tennent et al., 2017).
  • Baseline biomarkers: MSM did not change glucose or insulin in adults whose values were mostly normal (Miller et al., 2021); in obese and diabetic mice it lowered elevated glucose (Sousa-Lima et al., 2016).
  • Sex: No trial reported sex-specific results. A completed Bergstrom-supported trial testing whether MSM limits estrogen-linked knee ligament looseness in young women has posted no results (NCT03747198).
  • Pre-existing conditions: Knee osteoarthritis is the condition with the most supportive data; obesity did not show metabolic benefit, and allergy data lack placebo control.
  • Age: Osteoarthritis trials enrolled adults aged 40–90 (mean 68 in one trial), so older adults are well represented (Kim et al., 2006; Debbi et al., 2011); younger trainees saw no knee benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No harm reaches High: adverse-event data come from small placebo-controlled trials lasting 16 weeks or less, which found no excess events, plus a single case report.

Medium 🟥 🟥

No harm reaches Medium: no controlled trial or comparative observational study has shown a statistically significant excess of any adverse event with MSM over placebo.

Low 🟥

Mild gastrointestinal upset and minor complaints ⚠️ Conflicted

Reported complaints include bloating, indigestion, headache, fatigue and insomnia (drugs.com monograph). In one trial, 3 of 11 runners on MSM reported mild stomach upset or insomnia versus none on placebo (Withee et al., 2017); pooled trials found no excess (Liu et al., 2018). Net: mild, not shown above placebo.

Magnitude: At 3 g/day, mild stomach effects occurred in 2 of 11 and insomnia in 1 of 11 versus none of 11 on placebo (Withee et al., 2017); at 6 g/day for 12 weeks (followed to week 16), adverse events occurred in 2 of 50 (one colitis, meaning colon inflammation, and one musculoskeletal pain) versus 2 of 50 on placebo, with laboratory values unchanged (NCT02268305; Crawford et al., 2019).

Acute angle-closure glaucoma

One case report described two-eye angle-closure glaucoma (blocked eye-fluid drainage causing a pressure spike) a week after starting three supplements, one containing MSM, resolving after all three were stopped (Hwang et al., 2015). The authors proposed a sulfa-drug mechanism (sulfonyl-containing antibiotics and diuretics, which increase urine output). Causation is unproven.

Magnitude: Not quantified in available studies. Only a single case report exists, with no control group or incidence data.

Speculative 🟨

Long-term brain accumulation

At 1–3 g/day, MSM reached 0.42–3.40 mmol/kg in human brain tissue without observed harm (Lin et al., 2001). Long-term consequences are unstudied; concern is mechanistic only.

Reproductive toxicity ⚠️ Conflicted

Dimethyl sulfone impaired fertility and shortened life in mutant worms (Goldstein et al., 1992), but rats showed no fetal harm up to 1,000 mg/kg/day (Magnuson et al., 2007). No human data exist. Net: unresolved.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to alter MSM safety; no data link it to variable drug-processing enzymes.
  • Kidney function: Most MSM leaves through urine in rats (Magnuson et al., 2007), so a low eGFR (estimated glomerular filtration rate, a kidney-function measure) could raise exposure (theoretical).
  • Sex and pregnancy: No sex differences in side effects are reported. Human pregnancy and breastfeeding safety is unstudied; rat studies showed no fetal harm (Magnuson et al., 2007).
  • Eye anatomy: People with narrow eye-drainage angles or prior angle-closure may face higher risk, by analogy with sulfa drugs (Hwang et al., 2015).
  • Sulfonamide (sulfa) drug allergy: MSM is not a sulfonamide and no cross-reaction is documented; the shared sulfonyl group is the only basis for concern (theoretical).
  • Age: Adults aged 45–90 took about 3.4 g/day for 12 weeks in one trial (Debbi et al., 2011); older adults’ larger medication lists raise interaction potential with multi-ingredient joint products.

Key Interactions & Contraindications

  • Prescription anticoagulants and antiplatelets (blood thinners: warfarin, apixaban, clopidogrel) — monitor (theoretical): No interaction has been documented (drugs.com monograph). Multi-ingredient joint products add other agents; an INR (international normalized ratio, a clotting test) check after starting would detect any rise in bleeding risk.
  • Drugs cleared by CYP enzymes (warfarin, atorvastatin, omeprazole) — no interaction expected (laboratory data): MSM did not inhibit seven CYP enzymes in human liver preparations (Kim et al., 2023), so altered blood levels of these drugs are not expected; no human study has confirmed this.
  • NSAIDs (nonsteroidal anti-inflammatory drugs such as naproxen, ibuprofen) — no interaction found: 6 g/day MSM with naproxen for 12 weeks caused no liver, kidney, blood-count or blood-pressure differences versus naproxen plus placebo (Crawford et al., 2019).
  • Drugs that can trigger angle closure (topiramate, acetazolamide, anticholinergics, which block the nerve messenger acetylcholine, such as diphenhydramine) — caution (theoretical): Combined use could add to acute angle-closure risk (Hwang et al., 2015); an eye check for narrow angles mitigates this.
  • Topical DMSO (dimethyl sulfoxide) — caution (theoretical): The body converts DMSO into MSM, so combined use raises total MSM exposure and could add to dose-related stomach upset; using one or the other avoids stacking.
  • Cannabidiol (CBD)-rich extracts — monitor (theoretical in humans): In mice, MSM plus CBD extract caused no liver injury and no added liver-enzyme induction (Kutanzi et al., 2020); no human study exists, and liver tests would detect injury with long-term combined use.
  • Glucosamine and chondroitin — additive (intended): MSM with glucosamine reduced pain and swelling more than either alone (Usha & Naidu, 2004), and adding MSM to glucosamine-chondroitin eased pain further (Lubis et al., 2017); consequence: added symptom relief, with no added harm reported.
  • Curcumin, boswellia and pine bark extracts — no interaction found: Co-administration did not change their blood levels in 16 volunteers (Liu et al., 2020), and 1.5 g/day MSM combinations matched placebo for adverse events over 12 weeks (Liu et al., 2021; Yuan et al., 2026).
  • Resistance and endurance training — no interaction shown: MSM did not change knee-extension work capacity after 28 days (Kalman et al., 2012); no consequence for training performance has been found.

Populations who should avoid MSM:

  • People with prior acute angle-closure glaucoma or known narrow eye-drainage angles (theoretical, based on one case report)
  • Pregnant or breastfeeding women (human safety data lacking, per the drugs.com monograph)
  • People with known hypersensitivity to MSM
  • People with advanced chronic kidney disease (theoretical, because MSM is cleared in urine)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Gradual dose escalation: Starting near 1 g/day and increasing over 1–2 weeks toward the target dose mitigates gastrointestinal upset and nausea.
  • Taking with meals: Taking each dose with food mitigates nausea and stomach discomfort, the most commonly described minor complaints.
  • Split dosing above 3 g/day: Dividing larger daily amounts into two or three doses, as trials did, mitigates gastrointestinal upset from single large doses.
  • Eye-symptom vigilance: Stopping MSM and seeking same-day eye care for sudden eye pain, blurred vision, halos or headache mitigates angle-closure damage; the reported case resolved 4 days after stopping (Hwang et al., 2015).
  • Baseline kidney check: Measuring creatinine and eGFR before using 3–6 g/day mitigates the theoretical risk of accumulation when kidney clearance is reduced.
  • Avoiding use in pregnancy: Pausing MSM during pregnancy and breastfeeding mitigates unknown developmental risk, given conflicting animal data.
  • Time-limited trial: Reassessing need after 12 weeks, the length of most trials, limits open-ended exposure and the unstudied long-term brain accumulation.

Therapeutic Protocol

Timing, cycling and titration steps below reflect common practice unless cited; doses are cited to their sources.

  • Osteoarthritis dosing: 1.5–6 g/day; trials used 500 mg three times daily (Usha & Naidu, 2004), 1.125 g three times daily (Debbi et al., 2011) and 3 g twice daily (Kim et al., 2006).
  • General and active-adult dosing: 3 g/day in exercise and metabolic trials (Withee et al., 2017; Miller et al., 2021); 2 g/day for mild knee pain (Toguchi et al., 2023).
  • Lower-dose approach: 1 g/day was used for skin (Muizzuddin & Benjamin, 2022) and for post-exercise immune gene activity (McFarlin et al., 2025).
  • Allergy dosing: 2.6 g/day (Barrager et al., 2002); 3 g/day was the most effective of the doses compared (Hewlings & Kalman, 2018).
  • Popularizers: Stanley Jacob and colleagues promoted MSM through “The Miracle of MSM” (1999); Bergstrom Nutrition’s OptiMSM is the ingredient used in most US trials.
  • Competing approaches: Conventional osteoarthritis care centers on exercise, weight loss and NSAIDs; integrative practice adds MSM alone or with glucosamine and chondroitin (Lubis et al., 2017). Trials tested MSM as an add-on and as stand-alone use.
  • Time of day: No study compared timing; taking doses with breakfast and an early evening meal is common practice.
  • Half-life: Rat half-life is about 12 hours (Magnuson et al., 2007); human half-life is not formally measured, but brain levels hold steady for at least 3 hours after a dose (Kaiser et al., 2020).
  • Single vs split dose: Once-daily doses of 1–6 g were used for 14 days in an allergy trial (Hewlings & Kalman, 2018); osteoarthritis trials split 1.5–6 g into two or three doses (Kim et al., 2006; Debbi et al., 2011).
  • Genetic polymorphisms: No known variant influences dose choice.
  • Sex differences: No sex-specific dosing exists; women made up most of the half-marathon trial (Withee et al., 2017), with the same dose as men.
  • Age: Osteoarthritis trials used standard doses in adults up to 90 years old.
  • Baseline biomarkers: No biomarker predicts response; baseline kidney function guides use of higher doses.
  • Pre-existing conditions: Knee osteoarthritis is the best-studied use; prior angle-closure glaucoma argues against use.

Discontinuation & Cycling

  • Short-term vs ongoing: Trials ran 10 days to 16 weeks; any joint benefit is symptomatic, so it would be expected to fade after stopping. No long-term data exist.
  • Withdrawal effects: None have been reported in any trial or case report.
  • Tapering: Not needed; MSM can be stopped at once.
  • Cycling: No evidence supports or requires cycling to maintain effect.
  • Reassessment point: A review of symptoms at 12 weeks, matching trial length, helps decide whether to continue.

Sourcing and Quality

  • Production and purity: Commercial MSM is made by oxidizing DMSO and then purifying it by distillation or crystallization; distilled, single-ingredient products with a stated purity of 99% or more limit solvent residues.
  • Forms: Capsules, tablets, powders and flakes are available, plus topical creams; Examine notes the best evidence is for oral tablets (Examine).
  • Third-party testing: USP (United States Pharmacopeia, a drug and supplement standards body) or NSF (NSF International, a product-certification body) certification, or ConsumerLab approval, verifies content; 18% of joint-health products failed ConsumerLab testing (ConsumerLab).
  • Branded ingredient: OptiMSM (Bergstrom Nutrition) is the distilled ingredient used in many trials; Doctor’s Best Glucosamine Chondroitin MSM with OptiMSM uses it, and Life Extension MSM 1000 mg is another widely sold single-ingredient option.
  • Combination products: Glucosamine-chondroitin-MSM blends often supply 500–1,500 mg MSM per serving, below most trial doses; checking the per-serving amount avoids under-dosing.

Practical Considerations

  • Time to effect: Osteoarthritis trials measured differences at 4–12 weeks (Lubis et al., 2017; Debbi et al., 2011); allergy symptoms improved within 7 days in an uncontrolled study (Barrager et al., 2002).
  • Common pitfalls: Under-dosing through combination products, expecting cartilage rebuilding (no trial measured structure), and judging benefit from short, unblinded self-experiments.
  • Regulatory status: MSM is sold in the US as a dietary supplement (drugs.com monograph); the FDA had “no questions” about its use as a food ingredient after Bergstrom’s GRAS notice (FDA GRAS Notice No. 229).
  • Evidence sponsorship: Many trials used Bergstrom’s OptiMSM or were run by manufacturers; the larger independent trials in healthy adults were null, which matters when weighing claims.
  • Cost and access: MSM is inexpensive and widely available, so cost is rarely a barrier.

Interaction with Foundational Habits

  • Sleep: Direct, possibly disruptive. Insomnia is a listed complaint (drugs.com monograph) and was reported by 1 of 11 runners on 3 g/day versus none on placebo (Withee et al., 2017); no trial measured sleep quality. Taking doses earlier in the day is a common precaution.
  • Nutrition: Indirect. Methionine and cysteine from eggs, meat, fish, dairy and legumes are the main dietary sulfur sources (Wong et al., 2017); MSM occurs in fresh foods but is lost with heating or drying (drugs.com monograph). Taking it with meals limits stomach upset.
  • Exercise: None shown. MSM did not change exercise performance (Kalman et al., 2012) or significantly reduce soreness; whether antioxidant effects blunt training adaptations is unstudied. Exercise itself remains the core osteoarthritis treatment.
  • Stress management: None shown. 3 g/day for 8 weeks did not change any of six mood-state scales in military trainees (Tennent et al., 2017), and no cortisol effect is documented.

Monitoring Protocol & Defining Success

Before starting, a baseline assessment establishes a reference point: a joint pain and function score such as WOMAC for the joint being targeted, serum creatinine with eGFR to confirm normal kidney clearance, ALT (alanine aminotransferase, a liver enzyme) as a safety reference, and hs-CRP (high-sensitivity C-reactive protein, a general inflammation marker) if an anti-inflammatory effect is hoped for. For anyone with a history of eye pressure problems, an eye examination of the drainage angles is part of the baseline.

Ongoing monitoring follows this cadence: symptom scores at 4 and 12 weeks, then every 6 months; creatinine, eGFR and ALT at 12 weeks for doses of 3 g/day or more, then every 12 months; hs-CRP at 12 weeks only if measured at baseline. Success is a sustained drop in pain or rise in function by 12 weeks without new symptoms.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine / eGFR Creatinine about 0.7–1.3 mg/dL in men and 0.6–1.1 mg/dL in women; eGFR 60 mL/min/1.73 m² or higher (standard reference range) Safety check: MSM is cleared in urine Ranges vary by laboratory; no change occurred at 6 g/day for 12 weeks (Crawford et al., 2019); heavy exercise or large meat meals in the 24 hours before testing can raise creatinine
ALT About 7–55 U/L (standard reference range) Safety check, especially with other supplements Ranges vary by laboratory; unchanged at 6 g/day (Crawford et al., 2019); usually paired with AST (aspartate aminotransferase, a second liver enzyme)
hs-CRP No established target; track change from the individual’s own baseline Marker MSM is proposed to change (human data inconclusive) Infection and hard exercise within the prior 48 hours raise values temporarily; in one trial values stayed flat with MSM while rising on placebo (Miller et al., 2021)

Qualitative markers:

  • Joint pain during daily activities and after exercise
  • Morning stiffness duration
  • Ease of stairs, walking distance and getting up from a chair
  • Post-workout muscle soreness and recovery time
  • Seasonal nasal symptoms, if allergy relief is a goal
  • Gastrointestinal comfort and any new eye symptoms

Emerging Research

  • Collagen-plus-MSM skin trial: A placebo-controlled trial of collagen, MSM and vitamin C on facial redness in 90 adults over 16 weeks (NCT07345195) is listed as not yet recruiting, completion November 2026. A positive result would support combination skin effects, not MSM alone; a null result would weaken skin claims.
  • Hair-density trial: A collagen, MSM and biotin drink was compared with placebo in 89 adults over 24 weeks (NCT06174441); it completed in October 2024 with no results posted.
  • Knee laxity in young women: A trial of 2 g/day versus placebo on menstrual-cycle knee looseness in 32 women (NCT03747198) completed in 2019, with no results posted.
  • Longer osteoarthritis trial: A 26-week trial of 6 g/day in 100 people with hip or knee osteoarthritis (NCT01836757) passed its 2013 completion date with unknown status and no posted results. Life Extension Magazine, from an MSM seller, reports 2014 published results of less pain and better function than placebo; that report is not retrievable online.
  • Low-dose immune signaling: In a 10-runner pilot, 1 g/day for 30 days changed 29 immune-related gene messages after a half-marathon (McFarlin et al., 2025), a lead that larger trials could confirm or refute.
  • Combination null trials: Multi-ingredient products with 1.5 g/day MSM did not beat placebo for hand (Liu et al., 2021) or knee osteoarthritis (Yuan et al., 2026), weakening the multi-ingredient case.
  • Aging biology gap: No lifespan study in mammals exists; mouse bone data (Aljohani et al., 2021) and a worm study showing shorter life at high exposure (Goldstein et al., 1992) point in different directions.

Conclusion

MSM is an inexpensive, sulfur-containing supplement that the body also makes in small amounts. Its best-supported use is easing knee arthritis pain and improving joint function, where trials from several independent groups agree on a modest short-term benefit, although combined analyses of the trials disagree on whether the gain is large enough to matter. For active adults without arthritis, a larger independent trial found no clear improvement in knee comfort or mood, a trial in people with chronic back pain reported similar pain scores with and without it, and claims for faster exercise recovery, allergy relief, skin, hair, heart health and cancer rest on small, uncontrolled or animal studies.

Safety looks favorable within the studied range and time frame. Side effects in controlled trials were mild and no more common than with placebo, kidney, liver and blood tests did not change, and the only serious concern is a single report of a sudden eye-pressure emergency. Long-term use beyond a few months, use in pregnancy and the meaning of MSM building up in brain tissue remain unstudied.

The evidence base is thin and leans heavily on a single ingredient maker, Bergstrom Nutrition, which supplied product for or co-authored many studies and filed the food-safety notice, while a supplement seller’s magazine supplies much of the popular framing. Nothing ties MSM to longer life. For health-focused adults, it is best understood as a low-risk, low-cost option with a modest, uncertain payoff for arthritic knees and little demonstrated value beyond them.

Top - Benefits - Risks - Protocol